Detalhe da pesquisa
1.
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
J Crohns Colitis
; 15(10): 1694-1706, 2021 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786600
2.
Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned.
Inflamm Bowel Dis
; 24(1): 2-4, 2017 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29272481